Nairobi – Kenya is poised to take a major leap forward in the fight against HIV with plans to introduce Lenacapavir, a revolutionary long-acting injectable drug that offers six months of HIV prevention from a single dose.
The announcement follows the World Health Organization’s (WHO) recent approval of the drug, coming just days after it received clearance from the U.S. Food and Drug Administration (FDA). Health experts are hailing Lenacapavir as a “game changer” in the global battle against HIV—especially in high-burden countries like Kenya.
Speaking before the Senate Standing Committee on Labour, Dr. Patrick Amoth, Director General at Kenya’s Ministry of Health, confirmed that the country is targeting an early 2026 rollout of the injection. The ministry is partnering with global institutions like the Global Fund to lay the groundwork for nationwide deployment.
“This is a significant milestone in HIV prevention,” said Dr. Amoth. “We’ve had oral PrEP for a while, but many people, especially young people, struggle to take a pill every day. With Lenacapavir, one injection gives protection for half a year.”
While optimism is high, Dr. Amoth stressed that Kenya is not ready to launch immediately. Key preparations—such as training healthcare personnel, strengthening cold-chain systems, and enhancing supply chain infrastructure—must be completed first.
“If all systems were in place, we’d launch today,” he said. “But we are on track to begin in January 2026.”
Health Cabinet Secretary Aden Duale echoed the urgency and importance of the new drug, calling it a “vital addition” to Kenya’s HIV prevention arsenal.
“We’re working closely with our partners to make this available as soon as possible,” said Duale. “It’s a breakthrough that’s been approved by global health authorities and is timely for our youth, who remain at the highest risk.”
Recent data from the National Syndemic Diseases Control Council (NSDCC) reveals the urgency behind the rollout: Kenya recorded over 22,000 new HIV infections in 2023, with adolescents and young adults making up the majority of new cases.
Lenacapavir is part of a new generation of drugs known as capsid inhibitors. It works by blocking the HIV virus’s ability to replicate and spread, offering a powerful tool especially for high-risk groups such as sex workers, men who have sex with men (MSM), and young people—populations that often face challenges with adherence to daily oral PrEP due to stigma or forgetfulness.
To ensure successful implementation, the Ministry of Health plans to:
-
Train healthcare workers across the country on proper administration and patient management
-
Launch public awareness campaigns to combat stigma and boost uptake
-
Develop monitoring systems to track the injection’s effectiveness and community acceptance
If the 2026 timeline is met, Kenya could become one of the first African countries to introduce Lenacapavir at scale, marking a turning point in HIV prevention efforts on the continent.
About The Author
